​

Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RARE Stock Forecast

Ultragenyx Pharmaceutical (RARE) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $90.00, with a high of $95.00 and a low of $85.00. This represents a 111.91% increase from the last price of $42.47.

$40 $51 $62 $73 $84 $95 High: $95 Avg: $90 Low: $85 Last Closed Price: $42.47

RARE Stock Rating

Ultragenyx Pharmaceutical stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (82.35%), 2 Hold (11.76%), 1 Sell (5.88%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 1 2 14 Strong Sell Sell Hold Buy Strong Buy

RARE Forecast vs Benchmarks

TypeNameUpside
StockUltragenyx Pharmaceutical111.91%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-29
Avg Price Target-$90.00$105.11
Last Closing Price$42.47$42.47$42.47
Upside/Downside-111.91%147.49%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 257131--21
Dec, 247131--21
Nov, 247137-128
Oct, 247137-128
Sep, 247137-128
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Ed ArceH.C. Wainwright$95.00$51.2085.55%123.69%
Nov 06, 2024Joseph SchwartzLeerink Partners$85.00$51.2066.02%100.14%
Jun 06, 2024Salveen RichterGoldman Sachs$67.00$41.4561.64%57.76%
May 31, 2024Dae Gon HaStifel Nicolaus$127.00$38.65228.59%199.03%
May 31, 2024Christopher RaymondRaymond James$135.00$38.65249.29%217.87%
May 31, 2024Joel BeattyRobert W. Baird$72.00$38.6586.29%69.53%
May 31, 2024Whitney IjemCanaccord Genuity$111.00$38.65187.19%161.36%
Apr 15, 2024Dae Gon HaStifel Nicolaus$124.00$42.87189.25%191.97%
Apr 15, 2024Christopher RaymondRaymond James$130.00$42.87203.24%206.10%
Feb 03, 2023Morgan Stanley$95.00$47.03102.00%123.69%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2024Wells FargoBuyBuyhold
Oct 01, 2024Cowen & Co.BuyBuyhold
Sep 20, 2024Wells FargoBuyBuyhold
Aug 02, 2024WedbushNeutralNeutralhold
Aug 02, 2024Cantor FitzgeraldOverweightOverweighthold
Jul 22, 2024WedbushBuyBuyhold
Jun 17, 2024Cowen & Co.BuyBuyhold
May 31, 2024BarclaysOverweightOverweighthold
May 31, 2024WedbushBuyBuyhold
May 31, 2024Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$-15 $-9 $-3 $3 $9 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.07$-6.70$-10.12$-8.25-----
Avg Forecast$-3.79$-6.25$-9.92$-8.37$-6.21$-5.11$-3.40$-0.17$4.13
High Forecast$-4.26$-7.03$-10.84$-9.13$-6.64$-6.32$-5.82$-9.87$4.02
Low Forecast$-3.62$-5.97$-8.61$-7.92$-5.92$-3.82$-0.80$10.08$4.20
Surprise %-19.00%7.20%2.02%-1.43%-----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$271.03M$351.41M$363.33M$434.25M-----
Avg Forecast$250.02M$351.78M$361.74M$428.63M$546.66M$645.00M$858.55M$1.22B$1.83B
High Forecast$241.23M$339.42M$325.03M$423.24M$536.88M$643.00M$846.38M$1.17B$1.79B
Low Forecast$273.74M$385.16M$387.56M$432.53M$556.16M$647.02M$870.71M$1.28B$1.85B
Surprise %8.40%-0.11%0.44%1.31%-----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-186.57M$-454.02M$-707.42M$-606.64M-----
Avg Forecast$-176.32M$-396.60M$-413.87M$-606.64M$-461.94M$-372.86M$-338.45M$13.07M$303.83M
High Forecast$-232.24M$-475.92M$-496.64M$-727.97M$-488.37M$-464.57M$-427.75M$-725.65M$295.72M
Low Forecast$-120.40M$-317.28M$-331.09M$-485.31M$-435.51M$-281.15M$-58.80M$741.13M$309.09M
Surprise %5.81%14.48%70.93%------

RARE Forecast FAQ

Is Ultragenyx Pharmaceutical stock a buy?

Ultragenyx Pharmaceutical stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Ultragenyx Pharmaceutical is a favorable investment for most analysts.

What is Ultragenyx Pharmaceutical's price target?

Ultragenyx Pharmaceutical's price target, set by 17 Wall Street analysts, averages $90 over the next 12 months. The price target range spans from $85 at the low end to $95 at the high end, suggesting a potential 111.91% change from the previous close price of $42.47.

How does Ultragenyx Pharmaceutical stock forecast compare to the average forecast of its sector, industry, and investment themes?

Ultragenyx Pharmaceutical stock forecast shows a 111.91% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Ultragenyx Pharmaceutical over the past three months?

  • January 2025: 33.33% Strong Buy, 61.90% Buy, 4.76% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 33.33% Strong Buy, 61.90% Buy, 4.76% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 25.00% Strong Buy, 46.43% Buy, 25.00% Hold, 0% Sell, 3.57% Strong Sell.

What is Ultragenyx Pharmaceutical’s EPS forecast?

Ultragenyx Pharmaceutical's average annual EPS forecast for its fiscal year ending in December is -6.21 for 2024, a -24.73% decrease from the reported $-8.25 in 2023. The prediction for 2025 is $-5.11, $-3.4 for 2026, $-0.17 for 2027, and $4.13 for 2028.

What is Ultragenyx Pharmaceutical’s revenue forecast?

Ultragenyx Pharmaceutical's average annual revenue forecast for its fiscal year ending in December is $546.66M for 2024, a 25.89% increase from the reported $434.25M in 2023. The forecast for 2025 is $645M, $858.55M for 2026, $1.22B for 2027, and $1.83B for 2028.

What is Ultragenyx Pharmaceutical’s net income forecast?

For its fiscal year ending in December, Ultragenyx Pharmaceutical's average annual net income forecast is $-462M for 2024, reflecting a -23.85% decrease from the reported $-607M in 2023. The projection for 2025 is $-373M, $-338M for 2026, $13.07M for 2027, and $303.83M for 2028.